ClinicalTrials.gg
RecruitingNCT05971732COREVIVE-HFrEFUpdated Nov 6, 2026

The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life(COREVIVE-HFrEF)

A Phase 4 interventional study of Ferric derisomaltose and Placebo in Heart Failure With Reduced Ejection Fraction, Iron Deficiency and Acute Heart Failure, sponsored by China-Japan Friendship Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by China-Japan Friendship Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2023; still recruiting 3 years 3 months later.
Updated Nov 6, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
146
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 21 studies testing iron isomaltoside 1000 in Iron Deficiencies — 9 open to participants now, 9 under way, 2 of them phase 3. iron isomaltoside 1000 · Iron Deficiencies.

Planned enrollment
12th of 21
146 · median 170
Started
2023
with 2 others
Phase 4
7 of 21
5 open now
Registered
14th of 21
by date
Lead sponsor
4 of 21
China-Japan Friendship Hospital

Among the 21 studies testing iron isomaltoside 1000 in Iron Deficiencies, this one is the 12th largest by planned enrollment, is one of 3 that started in 2023, is one of 7 in phase 4, and was the 14th registered.

Iron Deficiencies

386 studies on the registry are indexed under Iron Deficiencies; 78 are open to participants now.

Browse Iron Deficiencies studies →

Open to participants now

9 of the 21 studies testing iron isomaltoside 1000 in Iron Deficiencies are open now, in 4 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About iron isomaltoside 1000

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 53 Iron Deficiencies studies recruiting now, 23 (43%) set no upper age limit and 26 (49%) stop at 75 or younger; 14 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing iron isomaltoside 1000 in Iron Deficiencies, or all of them as a file.
02

Study summary

This study will address whether the additional use of Ferric Derisomaltose on top of standard care will improve exercise capacity and quality of life in patients with acute heart failure and iron deficiency. One group of participants will receive treatment with Ferric Derisomaltose and the other group will receive normal saline 0.9% as placebo.

Read the detailed description

Acute heart failure (AHF) is a very common medical problem. Despite improvements in treatment, many patients suffer limiting exercise capacity and quality of life. Previous comorbidities may account for it. Approximately 80% of patients hospitalized with AHF suffered from a combination of iron deficiency. A decline in exercise capacity may occur under this condition. Some research studies have suggested that giving CHF patients intravenous iron improves symptoms in the short term. It is unknown, however, whether correcting iron deficiency is beneficial to patients with AHF to improve excise capacity and whether it improves quality of life and accelerate recovery from acute duration. This study will help us answer these key questions.

This is an investigator-initiated, randomised, parallel group, double-blind, placebo-controlled trial, evaluating the excise capacity improvement of using ferric derisomaltose versus placebo in hospitalized patients with acute heart failure with reduced ejection fraction before discharge.

Participants will be assessed daily using 6-minute walking test after IV iron injection until discharge from hospital, especially focus on the change from baseline to the 3rd day. Some questionnaires are also conducted to evaluate the self-reported status. Participants will be followed up at 2 weeks and 4 weeks.

The primary and secondary endpoints will be examined in subgroups predefined by baseline variables reflecting demography, Hb level, etiology of HF, left ventricular ejection fraction, natriuretic peptide, index of iron metabolism, eGFR and others.

03

Conditions studied

  • Heart Failure With Reduced Ejection Fraction
  • Iron Deficiency
  • Acute Heart Failure

Browse trials for

Keywords

  • Exercise capacity
  • Quality of life
  • Acute Heart Failure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years.
  2. Clinical diagnosis of heart failure with reduced (HFrEF), defined as documented 2-dimensional echocardiography left ventricular ejection fraction (LVEF) \<50% before randomization.
  3. Currently hospitalised for an episode of acute heart failure (AHF) where AHF was the primary reason for hospitalisation, (NYHA) class II - IV.
  4. Reaching hemodynamic stability after standard treatment (if tolerated, initiate four pillars of guideline-directed medical therapies). All of the following (i.e., items a to c) must apply:

    1. Systolic blood pressure≥100mmHg, without symptoms of hypotension;
    2. Stop using intravenous diuretics;
    3. Neither intravenous inotropic drugs or vasodilators were used (including nitrates).
  5. Subject is iron deficient defined as serum ferritin \<100 ng/mL or 100 ng/mL ≤ serum ferritin ≤299 ng/mL if TSAT \<20%.
  6. Able and willing to provide and accomplish 6 minutes-walking test.

Exclusion criteria

Exclusion Criteria:

  1. Hematological criteria: ferritin >400 ug/L; \<9.0, hemoglobin >13.5 g/dL in women or >14.5 g/dL in men.
  2. Renal dialysis or /CKD-EPI estimated glomerular filtration rate (eGFR) \<15ml/min/1.73m2
  3. Body weight \<35kg at randomization.
  4. Heart failure was secondary to valvular diseases or congenital heart diseases.
  5. History of acquired iron overload or hemochromatosis (or first-degree relative of hemochromatosis)
  6. Known reaction to any component of ferric derisomaltose (Monofer®) or any of its (water for injections, sodium hydroxide (for pH adjustment), hydrochloric acid (for pH adjustment)).
  7. Non-iron deficiency anaemia.
  8. Already receiving erythropoiesis stimulating agents (ESA) or other iron supplements in previous 4 weeks prior to randomization.
  9. Active infection (defined as currently treated with oral or intravenous antibiotics), bleeding (gastrointestinal haemorrhagia, menorrhagia, history of peptic ulcer with no evidence of healing or inflammatory bowel disease) and history of malignant tumor.
  10. Any of the following diseases that hinders exercise testing: severe musculoskeletal disease, unstable angina, obstructive cardiomyopathy, severe uncorrected valvular disease, or uncontrolled slow or rapid arrhythmia (mean ventricular rate> 100 beats / min at rest).
  11. Known positive and/or ; known positivity; chronic liver disease (including active hepatitis), hepatic sclerosis, or AST > 3x .
  12. Within 3 months of any of the following: acute myocardial infarction (AMI) or acute coronary syndrome (ACS), (TIA) or stroke, uncontrolled hypertension.
  13. Revascularization therapy (coronary artery bypass grafting, percutaneous intervention, or major surgery) in the past 3 months; or planning cardiac surgery or revascularization.
  14. Baseline 6 minutes-walking distance>500m.
  15. Treated with long-term oral high-dose or - therapy.
  16. Investigator considers a possible alternative diagnosis to explain the patient's HF symptoms: severe obesity, primary pulmonary hypertension, or (COPD).
  17. Subject is pregnant (e.g., positive human chorionic gonadotropin test) or breast feeding.
  18. Untreated hypothyroidism.
  19. Currently enrolled in any other device or drug study \<30 days prior to screening, or received other investigational agent(s).
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
146 participants (estimated)

Study arms

  • Experimental
    Ferric derisomaltose

    Iron to be administered as ferric derisomaltose. The treatment dose (mL) to be administered will be determined by the patient's body weight and hemoglobin (Hb) value. Where Hb ≥10 g/dL, dosage according to body weight is as follows: Body weight \<50 kg: 20 mg/kg; Body weight 50 to \<70 kg: 1000 mg; Body weight ≥70 kg: 20 mg/kg up to a maximum of 1500 mg. Where Hb \<10 g/dL, dosage according to body weight is as follows: Body weight \<50 kg: 20 mg/kg; Body weight 50 to \<70 kg: 20 mg/kg; Body weight ≥70 kg: 20 mg/kg up to a maximum of 2000 mg. Infused over a minimum of 15mins for doses up to and including 1000mg, and a minimum of 30 mins for doses \>1000mg

    Drug: Ferric derisomaltose

  • Placebo comparator
    Placebo

    Participants in this arm will receive normal saline 0.9% in analogy to treatment arm.

    Drug: Placebo

Interventions

  • DrugIron isomaltoside 1000Studies of Iron isomaltoside 1000Iron isomaltoside 1000 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    After baseline assessments patients will be randomised in a 1:1 ratio to receive ferric derisomaltose IV or placebo (normal saline). In the Treatment group, Ferric derisomaltose will be administered according to the dosing schedule.

    Also known as: Monofer, Iron (III) isomaltoside 1000

  • DrugPlacebo

    In the placebo group, patients will receive the equivalent number of normal saline injections.

    Also known as: Normal saline

06

What researchers measure

Primary outcomes

  1. Change in 6-minute walking distance

    The difference of 6-minute walking distance in meters from baseline to day3 after IV iron injection.

    Time frame: Up to 3 days

Secondary outcomes

  1. Change From Baseline in 6-minute walking distance

    The difference of 6-minute walking distance in meters from baseline at 2 weeks, 4weeks after IV iron injection.

    Time frame: At 2 weeks, 4weeks after IV iron injection

  2. Change From Baseline in the KCCQ Clinical Summary Score

    KCCQ was a 23-item, self-administered questionnaire that measure the participant's perception of their health status, including their heart failure (HF) symptoms, impact on physical and social function and how their HF impacts the quality of life. KCCQ quantifies 7 domains: physical limitations (6 items), symptom stability (1 item), symptom frequency (4 items), symptom burden (3 items), self-efficacy (2 items), quality of life (3 items) and social limitations (4 items). Scores were generated for each domain and scaled from 0 to 100, with 0 denoting the worst and 100 the best possible status. KCCQ-clinical summary score was average of domains- physical limitation and total symptoms (average of symptom frequency and symptom burden), and transformed to a single score which ranged from 0 (worst) -100 (the best possible status), where the higher score reflected better health status.

    Time frame: At 2 weeks, 4weeks after IV iron injection

  3. Change From Baseline in the EQ-5D-5L Questionnaire Indexed Value

    EQ-5D-5L: European Quality of Life-5 Dimensions-5 Levels The EQ 5D questionnaire consists of a health descriptive system for participants to self-classify and rate their health status on the day of administration. The descriptive system includes 5 items/dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression, which are coded from 1 (best state) to 5 (worst state).

    Time frame: At 3 days, 2weeks, 4weeks after IV iron injection

  4. Change From Baseline in NYHA Functional Class

    NYHA = New York Heart Association NYHA functional class was assessed as Class I, II, III, IV: Class I - No symptoms and no limitation in ordinary physical activity, e.g. shortness of breath when walking, climbing stairs etc. Class II - Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity. Class III - Marked limitation in activity due to symptoms, even during less-than-ordinary activity. Comfortable only at rest. Class IV - Severe limitations. Experiences symptoms even while at rest. Lower response categories are better for score NYHA.

    Time frame: At 3 days, 2weeks, 4weeks after IV iron injection

  5. Change From Baseline in PGA quality of life questionnaire

    PGA:Patient Global Assessment PGA questionnaire consists of a health descriptive system for participants to self-reported and rate their medical condition after participate this study. The descriptive system includes 7 choices:has much improved, has (moderately) improved, has a little improved, is unchanged, is a little worse, is (moderately) worse, is much worse, which are coded from 1 (best state) to 7 (worst state).

    Time frame: At 3 days, 2weeks, 4weeks after IV iron injection

  6. Change From Baseline in Concentration of hemoglobin (Hb)

    Hemoglobin (Hb) is a commonly used clinical test for assessing anaemia, with units of g/L.

    Time frame: At 3 days, 2weeks, 4weeks after IV iron injection

  7. Change From Baseline in proportion of reticulocyte (Ret%)

    The reticulocyte ratio is often used to reflect the hematopoiesis of the bone marrow erythrocyte with units of percentage(%).

    Time frame: At 3 days, 2weeks, 4weeks after IV iron injection

  8. Change From Baseline in Concentration of ferritin

    To assess the effect of ferric derisomaltose vs. placebo on change in ferritin from baseline to 3 days, 2weeks and 4weeks

    Time frame: At 3 days, 2weeks, 4weeks after IV iron injection

  9. Change From Baseline in concentration of transferrin saturation

    To assess the effect of ferric derisomaltose vs. placebo on change in transferrin saturation from baseline to 3 days, 2weeks and 4weeks

    Time frame: At 3 days, 2weeks, 4weeks after IV iron injection

  10. Change From Baseline in Concentration of serum transferrin receptors (sTfR)

    To assess the effect of ferric derisomaltose vs. placebo on change in serum transferrin receptors (sTfR) from baseline to 3 days, 2weeks and 4weeks

    Time frame: At 3 days, 2weeks, 4weeks after IV iron injection

  11. Change From Baseline in Concentration of N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)

    To assess the effect of ferric derisomaltose vs. placebo on change in NT-proBNP from baseline to 3 days, 2weeks and 4weeks

    Time frame: At 3 days, 2weeks, 4weeks after IV iron injection

  12. Change From Baseline in Left Ventricular Systolic Function

    Left ventricular ejection fraction is assessed by two-dimensional directed M-mode echocardiography.

    Time frame: At 2weeks, 4weeks after IV iron injection

  13. Change From Baseline in Left Ventricular End-Diastolic Diameter

    Left ventricular end-diastolic diameter is assessed by two-dimensional directed M-mode echocardiography.

    Time frame: At 2weeks, 4weeks after IV iron injection

Other outcomes

  1. Change From Baseline in Urine Albumin-to-Creatinine Ratio (UACR)

    Urine Albumin-to-Creatinine Ratio (UACR) is regard as a safety endpoint to reflect early injury of kidney.

    Time frame: At 3 days, 2weeks, 4weeks after IV iron injection

  2. A rise of high-sensitivity C-reaction protein (hs-CRP) levels from baseline

    Safety endpoint is defined as a rise of high-sensitivity C-reaction protein (hs-CRP) from baseline.

    Time frame: Up to 4weeks

  3. Adverse Event after IV iron injection

    Adverse Event Include Fishbane symptoms (flushing/chest pain/back pain/chest tightness, sometimes with dyspnea), isolated signs and symptoms (urticaria/pruritus/rash/mild hypotension, hypertension/tachycardia/nausea/headache), signs and symptoms of allergic reactions (persistent hypotension; airway angioedema/generalised urticaria, non-airway angioedema/wheezing, bronchospasm, vomiting, abdominal pain, etc.)

    Time frame: Up to 4weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Aug 2027, 48 months after the start.

Of 26 phase 4 interventional studies under Iron Deficiencies, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 64. This study's planned 48 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Aug 2024 → Aug 2027 and completion Aug 2025 → Aug 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2023
First posted
Aug 2, 2023
StartActual
Aug 1, 2023
Primary completionEst.
Aug 1, 2027was Aug 2024
CompletionEst.
Aug 1, 2027was Aug 2025
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • China-Japan Friendship Hospital · Beijing, China
Show 1 removed
  • China-Japan Friendship Hospital · Beijing, China
Nov 6, 2026
Primary completion
Aug 1, 2024→Aug 1, 2027
Nov 6, 2026
Study completion
Aug 1, 2025→Aug 1, 2027
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    1 site added, 1 site removed
    Show site
    • China-Japan Friendship Hospital · Beijing, China
    Show 1 removed
    • China-Japan Friendship Hospital · Beijing, China
    Primary completion Aug 1, 2024→Aug 1, 2027
    Study completion Aug 1, 2025→Aug 1, 2027
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05971732
Responsible party
Jingyi Ren (Professor, China-Japan Friendship Hospital) — Principal investigator
First posted
Aug 2, 2023
Start date
Aug 1, 2023
Primary completion
Aug 1, 2027 (estimated)
Completion
Aug 1, 2027 (estimated)
Last update
Nov 6, 2026

Study contacts

Ying Zhou, Dr
Contact
929352903@qq.com
+86-13699164283
Peizhao Li, Dr
Contact
lipz7014@163.com
+86-18443151740

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iron isomaltoside 1000

Start the discussion